Financials data is unavailable for this security.
View more
Year on year Tryptamine Therapeutics Ltd had revenues remain flat at 0.00, though the company grew net income from a loss of 8.22m to a smaller loss of 5.86m.
Gross margin | -- |
---|---|
Net profit margin | -357.70% |
Operating margin | -357.70% |
Return on assets | -84.69% |
---|---|
Return on equity | -121.54% |
Return on investment | -120.26% |
More ▼
Cash flow in AUDView more
In 2023, cash reserves at Tryptamine Therapeutics Ltd fell by 1.65m. Cash Flow from Financing totalled 2.39m or -- of revenues. In addition the company used 4.03m for operations while cash used for investing totalled 9.09k.
Cash flow per share | -0.0123 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0062 |
---|---|
Tangible book value per share | 0.0057 |
More ▼
Balance sheet in AUDView more
Current ratio | 7.82 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼